Clinical Trial Update: Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating regimens of vaniprevir (MK7009) for treatment-naive patients with chronic genotype 1 hepatitis C virus infection has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• vaniprevir (MK7009) (vaniprevir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chronic Genotype 1 Hepatitis C Virus Infection | Phase 2 | Status: WITHDRAWN